Funding for this research was provided by:
Gatsby Charitable Foundation (GAT3676)
Received: 21 October 2021
Accepted: 20 December 2022
First Online: 27 February 2023
Change Date: 5 March 2023
Change Type: Update
Change Details: This article has been updated to amend an author name.
: The protocol and associated documents have been reviewed and approved by London-Harrow Research Ethics Committee, reference 21/LO/0387.
: Informed consent will be sought from patients and carers.
: BRB currently serves as co-Editor in Chief for the Journal of Parkinson’s disease, serves on the editorial of Practical Neurology and Digital Biomarkers, has received honoraria from serving on the scientific advisory board for Abbvie, Biogen and UCB, has received fees for speaking at conferences from AbbVie, Zambon, Roche, GE Healthcare and Bial and has received research support from the Netherlands Organization for Scientific Research, the Michael J Fox Foundation, UCB, Abbvie, the Stichting Parkinson Fonds, the Hersenstichting Nederland, the Parkinson’s Foundation, Verily Life Sciences, Horizon 2020 and the Parkinson Vereniging.EJH received funding from the National Institute of Health Technology (NIHR), the Gatsby Foundation and Parkinson’s UK; received fees for speaking and consultancy from Profile pharma Medicys and Luye and received travel support from Bial Abbvie and Ever pharma.YBS is a recipient of a Radboud Excellence award. He has received research support from the UK Medical Research Council, Wellcome Trust, NIHR, Parkinson’s UK, Versus Arthritis, Gatsby Foundation, Dunhill Trust.SKLD was supported in part by a Parkinson’s Foundation-Postdoctoral Fellowship (PF-FBS-2026).The other authors declare that they have no competing interests.